The DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.
Chemotherapy for advanced gastric cancer
Open accessAbstract
BACKGROUND: Gastric cancer is the fifth most common cancer worldwide. In "Western" countries, most people are either diagnosed at an advanced stage, or develop a relapse after surgery with curative intent. In people with advanced disease, significant benefits from targeted therapies are currently limited to HER-2 positive disease treated with trastuzumab, in combination with chemotherapy, in first-line. In second-line, ramucirumab, alone or in combination with paclitaxel, demonstrated significant survival benefits. Thus, systemic chemotherapy remains the mainstay of treatment for advanced gastric cancer. Uncertainty remains regarding the choice of the regimen. OBJECTIVES: To assess the efficacy of chemotherapy versus best supportive care (BSC), combination versus single-agent chemotherapy and different chemotherapy combinations in advanced gastric cancer. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials, MEDLINE and Embase up to June 2016, reference lists of studies, and contacted pharmaceutical companies and experts to identify randomised controlled trials (RCTs). SELECTION CRITERIA: We considered only RCTs on systemic, intravenous or oral chemotherapy versus BSC, combination versus single-agent chemotherapy and different chemotherapy regimens in advanced gastric cancer. DATA COLLECTION AND ANALYSIS: Two review authors independently identified studies and extracted data. A third investigator was consulted in case of disagreements. We contacted study authors to obtain missing information. MAIN RESULTS: We included 64 RCTs, of which 60 RCTs (11,698 participants) provided data for the meta-analysis of overall survival. We found chemotherapy extends overall survival (OS) by approximately 6.7 months more than BSC (hazard ratio (HR) 0.3, 95% confidence intervals (CI) 0.24 to 0.55, 184 participants, three studies, moderate-quality evidence). Combination chemotherapy extends OS slightly (by an additional month) versus single-agent chemotherapy (HR 0.84, 95% CI 0.79 to 0.89, 4447 participants, 23 studies, moderate-quality evidence), which is partly counterbalanced by increased toxicity. The benefit of epirubicin in three-drug combinations, in which cisplatin is replaced by oxaliplatin and 5-FU is replaced by capecitabine is unknown.Irinotecan extends OS slightly (by an additional 1.6 months) versus non-irinotecan-containing regimens (HR 0.87, 95% CI 0.80 to 0.95, 2135 participants, 10 studies, high-quality evidence).Docetaxel extends OS slightly (just over one month) compared to non-docetaxel-containing regimens (HR 0.86, 95% CI 0.78 to 0.95, 2001 participants, eight studies, high-quality evidence). However, due to subgroup analyses, we are uncertain whether docetaxel-containing combinations (docetaxel added to a single-agent or two-drug combination) extends OS due to moderate-quality evidence (HR 0.80, 95% CI 0.71 to 0.91, 1466 participants, four studies, moderate-quality evidence). When another chemotherapy was replaced by docetaxel, there is probably little or no difference in OS (HR 1.05; 0.87 to 1.27, 479 participants, three studies, moderate-quality evidence). We found there is probably little or no difference in OS when comparing capecitabine versus 5-FU-containing regimens (HR 0.94, 95% CI 0.79 to 1.11, 732 participants, five studies, moderate-quality evidence) .Oxaliplatin may extend (by less than one month) OS versus cisplatin-containing regimens (HR 0.81, 95% CI 0.67 to 0.98, 1105 participants, five studies, low-quality evidence). We are uncertain whether taxane-platinum combinations with (versus without) fluoropyrimidines extend OS due to very low-quality evidence (HR 0.86, 95% CI 0.71 to 1.06, 482 participants, three studies, very low-quality evidence). S-1 regimens improve OS slightly (by less than an additional month) versus 5-FU-containing regimens (HR 0.91, 95% CI 0.83 to 1.00, 1793 participants, four studies, high-quality evidence), however since S-1 is used in different doses and schedules between Asian and non-Asian population, the applicability of this finding to individual populations is uncertain. AUTHORS' CONCLUSIONS: Chemotherapy improves survival (by an additional 6.7 months) in comparison to BSC, and combination chemotherapy improves survival (by an additional month) compared to single-agent 5-FU. Testing all patients for HER-2 status may help to identify patients with HER-2-positive tumours, for whom, in the absence of contraindications, trastuzumab in combination with capecitabine or 5-FU in combination with cisplatin has been shown to be beneficial. For HER-2 negative people, all different two-and three-drug combinations including irinotecan, docetaxel, oxaliplatin or oral 5-FU prodrugs are valid treatment options for advanced gastric cancer, and consideration of the side effects of each regimen is essential in the treatment decision. Irinotecan-containing combinations and docetaxel-containing combinations (in which docetaxel was added to a single-agent or
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J. H., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055531 · Cited by 6,334
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
LAURÉN, P. (1965) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/apm.1965.64.1.31 · Cited by 6,133
WHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., Haller, D. G., Ajani, J. A., Gunderson, L. L., Jessup, J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010187 · Cited by 3,475
How should meta‐regression analyses be undertaken and interpreted?
Thompson, S. G., & Higgins, J. P. T. (2002) · Statistics in Medicine · doi:10.1002/sim.1187 · Cited by 3,026
Danaei, G., Ding, E. L., Mozaffarian, D., Taylor, B., Rehm, J., Murray, C. J. L., & Ezzati, M. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000058 · Cited by 2,860
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Sakuramoto, S., Sasako, M., Yamaguchi, T., Kinoshita, T., Fujii, M., Nashimoto, A., Furukawa, H., Nakajima, T., Ohashi, Y., Imamura, H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072252 · Cited by 2,517
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Ferrell, B. R., Temel, J. S., Temin, S., Alesi, E. R., Balboni, T. A., Basch, E. M., Firn, J. I., Paice, J. A., Peppercorn, J. M., Phillips, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1474 · Cited by 2,117
Ychou, M., Boige, V., Pignon, J.-P., Conroy, T., Bouché, O., Lebreton, G., Ducourtieux, M., Bedenne, L., Fabre, J.-M., Saint-Aubert, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0597 · Cited by 2,086
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8429 · Cited by 1,926
Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70035-4 · Cited by 1,847
Songun, I., Putter, H., Kranenbarg, E. M.-K., Sasako, M., & van de Velde, C. J. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70070-x · Cited by 1,765
Bang, Y.-J., Kim, Y.-W., Yang, H.-K., Chung, H. C., Park, Y.-K., Lee, K. H., Lee, K.-W., Kim, Y. H., Noh, S.-I., Cho, J. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61873-4 · Cited by 1,705
Extended Lymph-Node Dissection for Gastric Cancer
Bonenkamp, J. J., Hermans, J., Sasako, M., Welvaart, K., Songun, I., Meyer, S., Plukker, J. T. M., Van Elk, P., Obertop, H., Gouma, D. J., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401202 · Cited by 1,583
Sepúlveda, C., Marlin, A., Yoshida, T., & Ullrich, A. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00440-2 · Cited by 1,293
Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., & Fleig, W. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0245 · Cited by 1,171
Self-citationMuro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S., Eder, J. P., Golan, T., Le, D. T., Burtness, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00175-3 · Cited by 1,121
Ohtsu, A., Shah, M. A., Van Cutsem, E., Rha, S. Y., Sawaki, A., Park, S. R., Lim, H. Y., Yamada, Y., Wu, J., Langer, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2236 · Cited by 1,110
Webb, A., Cunningham, D., Scarffe, J. H., Harper, P., Norman, A., Joffe, J. K., Hughes, M., Mansi, J., Findlay, M., Hill, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.261 · Cited by 870
Glimelius, B., Ekström, K., Hoffman, K., Graf, W., Sjödén, P.-O., Haglund, U., Svensson, C., Enander, L.-K., Linné, T., Sellsröm, H., et al. (1997) · Annals of Oncology · doi:10.1023/a:1008243606668 · Cited by 849
Lordick, F., Kang, Y.-K., Chung, H.-C., Salman, P., Oh, S. C., Bodoky, G., Kurteva, G., Volovat, C., Moiseyenko, V. M., Gorbunova, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70102-5 · Cited by 833
Self-citationPyrhönen, S., Kuitunen, T., Nyandoto, P., & Kouri, M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.114 · Cited by 789
Al-Batran, S.-E., Hartmann, J. T., Probst, S., Schmalenberg, H., Hollerbach, S., Hofheinz, R., Rethwisch, V., Seipelt, G., Homann, N., Wilhelm, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9378 · Cited by 782
Kang, Y.-K., Kang, W.-K., Shin, D.-B., Chen, J., Xiong, J., Wang, J., Lichinitser, M., Guan, Z., Khasanov, R., Zheng, L., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn717 · Cited by 764
Systematic reviews of evaluations of prognostic variables
Altman, D. G. (2001) · BMJ · doi:10.1136/bmj.323.7306.224 · Cited by 756
Gastric cancer epidemiology and risk factors
Kelley, J. R., & Duggan, J. M. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00534-6 · Cited by 750
Kang, J. H., Lee, S. I., Lim, D. H., Park, K.-W., Oh, S. Y., Kwon, H.-C., Hwang, I. G., Lee, S.-C., Nam, E., Shin, D. B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4585 · Cited by 660
Satoh, T., Xu, R.-H., Chung, H. C., Sun, G.-P., Doi, T., Xu, J.-M., Tsuji, A., Omuro, Y., Li, J., Wang, J.-W., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6136 · Cited by 624
Ferro, A., Peleteiro, B., Malvezzi, M., Bosetti, C., Bertuccio, P., Levi, F., Negri, E., La Vecchia, C., & Lunet, N. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.029 · Cited by 617
Thuss-Patience, P. C., Kretzschmar, A., Bichev, D., Deist, T., Hinke, A., Breithaupt, K., Dogan, Y., Gebauer, B., Schumacher, G., & Reichardt, P. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.002 · Cited by 612
Ford, H. E. R., Marshall, A., Bridgewater, J. A., Janowitz, T., Coxon, F. Y., Wadsley, J., Mansoor, W., Fyfe, D., Madhusudan, S., Middleton, G. W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70549-7 · Cited by 595
Boku, N., Yamamoto, S., Fukuda, H., Shirao, K., Doi, T., Sawaki, A., Koizumi, W., Saito, H., Yamaguchi, K., Takiuchi, H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70259-1 · Cited by 586
Yamada, Y., Higuchi, K., Nishikawa, K., Gotoh, M., Fuse, N., Sugimoto, N., Nishina, T., Amagai, K., Chìn, K., Niwa, Y., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu472 · Cited by 567
Advanced gastric cancer: Current treatment landscape and future perspectives
Digklia, A. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i8.2403 · Cited by 560
Ajani, J. A., Rodriguez, W., Bodoky, G., Moiseyenko, V., Lichinitser, M., Gorbunova, V., Vynnychenko, I., Garin, A., Lang, I., & Falcon, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4706 · Cited by 550
Li, J., Qin, S., Xu, J., Guo, W., Xiong, J., Bai, Y., Sun, G., Yang, Y., Wang, L., Xu, N., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.8585 · Cited by 533
Vanhoefer, U., Rougier, P., Wilke, H., Ducreux, M. P., Lacave, A. J., Van Cutsem, E., Planker, M., Santos, J. G. D., Piedbois, P., Paillot, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.14.2648 · Cited by 531
Chau, I., Norman, A. R., Cunningham, D., Waters, J. S., Oates, J., & Ross, P. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.154 · Cited by 524
Ohtsu, A., Ajani, J. A., Bai, Y.-X., Bang, Y.-J., Chung, H.-C., Pan, H.-M., Sahmoud, T., Shen, L., Yeh, K.-H., Chin, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3552 · Cited by 483
Ross, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., Price, T., Anderson, H., Iveson, T., Hickish, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.105 · Cited by 475
Chemotherapy for advanced gastric cancer
Wagner, A. D., Unverzagt, S., Grothe, W., Kleber, G., Grothey, A., Haerting, J., & Fleig, W. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub3 · Cited by 472
Self-citationEllis, L. M., Bernstein, D. S., Voest, E. E., Berlin, J. D., Sargent, D., Cortazar, P., Garrett-Mayer, E., Herbst, R. S., Lilenbaum, R. C., Sima, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.8009 · Cited by 442
Ohtsu, A., Shimada, Y., Shirao, K., Boku, N., Hyodo, I., Saito, H., Yamamichi, N., Miyata, Y., Ikeda, N., Yamamoto, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.130 · Cited by 427
Gastric cancer—molecular and clinical dimensions
Wadhwa, R., Song, S., Lee, J.-S., Yao, Y., Wei, Q., & Ajani, J. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.170 · Cited by 423
Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A. M., Beretta, G. D., Ubiali, E., & Catalano, G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.061 · Cited by 421
Cullinan, S. A. (1985) · JAMA · doi:10.1001/jama.253.14.2061 · Cited by 391
Wils, J., Klein, H. O., Wagener, D. J. T., Bleiberg, H., Reis, H. E., Korsten, F. W., Conroy, T., Fickers, M. M. F., Leyvraz, S., & Buyse, M. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.5.827 · Cited by 388
Tan, I. B., Ivanova, T., Lim, K. H., Ong, C. W., Deng, N., Lee, J., Tan, S. H., Wu, J., Lee, M. H., Ooi, C. H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.042 · Cited by 357
Self-citationDank, M., Zaluski, J., Barone, C., Valvere, V., Yalcin, S., Peschel, C., Wenczl, M., Goker, E., Cisar, L., Wang, K., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn166 · Cited by 343
Epidemiology of upper gastrointestinal malignancies
CREW, K. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.04.021 · Cited by 323
Wildiers, H., Mauer, M., Pallis, A., Hurria, A., Mohile, S. G., Luciani, A., Curigliano, G., Extermann, M., Lichtman, S. M., Ballman, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6125 · Cited by 322
Wu, A. H., Wan, P., & Bernstein, L. (2001) · Cancer Causes & Control · doi:10.1023/a:1011290704728 · Cited by 297
Waters, J. S., Norman, A., Cunningham, D., Scarffe, J. H., Webb, A., Harper, P., Joffe, J. K., Mackean, M., Mansi, J., Leahy, M., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690350 · Cited by 275
Bouché, O., Raoul, J. L., Bonnetain, F., Giovannini, M., Etienne, P. L., Lledo, G., Arsène, D., Paitel, J. F., Guérin-Meyer, V., Mitry, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.140 · Cited by 274
Guimbaud, R., Louvet, C., Ries, P., Ychou, M., Maillard, E., André, T., Gornet, J.-M., Aparicio, T., Nguyen, S., Azzedine, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.1011 · Cited by 263
Ajani, J. A., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4968 · Cited by 250
Roth, A. D., Fazio, N., Stupp, R., Falk, S., Bernhard, J., Saletti, P., Köberle, D., Borner, M. M., Rufibach, K., Maibach, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0135 · Cited by 243
Histologic types of gastric carcinoma in high‐ and low‐risk areas
Muñóz, N., Correa, P., Cuello, C., & Duque, E. (1968) · International Journal of Cancer · doi:10.1002/ijc.2910030614 · Cited by 232
Van Cutsem, E., Kang, Y., Chung, H., Sawaki, A., Lordick, F., Hill, J., Lehle, M., Feyereislova, A., & Bang, Y. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.lba4509 · Cited by 203
Vickery, C. W., Blazeby, J. M., Conroy, T., Arraras, J., Sezer, O., Koller, M., Rosemeyer, D., Johnson, C. D., & Alderson, D. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00417-2 · Cited by 199
Helicobacter pylori and gastric cancer: state of the art.
Corréa, P. (1996) · PubMed · Cited by 186
Ajani, J. A., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3956 · Cited by 182
The JACCRO and KCSG Study Group, Koizumi, W., Kim, Y. H., Fujii, M., Kim, H. K., Imamura, H., Lee, K. H., Hara, T., Chung, H. C., Satoh, T., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1563-5 · Cited by 175
Life-style, workplace, and stomach cancer by subsite in young men of Los Angeles County.
Wu‐Williams, A. H., Yu, M. C., & Mack, T. M. (1990) · PubMed · Cited by 171
Al-Batran, S.-E., Pauligk, C., Homann, N., Hartmann, J. T., Moehler, M., Probst, S., Rethwisch, V., Stoehlmacher-Williams, J., Prasnikar, N., Hollerbach, S., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.09.025 · Cited by 165
Self-citationCost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer
Glimelius, B. L. G., Hoffman, K., Graf, W. D., Haglund, U., Nyrén, O., Påhlman, L., & Sjödén, P. O. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059157 · Cited by 162
Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
(2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.016 · Cited by 161
Pozzo, C., Barone, C., Szántó, J., Pádi, É., Peschel, C., Bükki, J., Горбунова, В. А., Valvere, V., Załuski, J., Biakhov, M. Y., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh473 · Cited by 158
EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors
Pallis, A. G., Ring, A., Fortpied, C., Penninckx, B., Van Nes, M. C., Wedding, U., vonMinckwitz, G., Johnson, C. D., Wyld, L., Timmer-Bonte, A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq687 · Cited by 158
Cascinu, S., Cordella, L., Ferro, E. D., Fronzoni, M., & Catalano, G. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.26 · Cited by 158
Kim, G. M., Jeung, H., Rha, S. Y., Kim, H. S., Jung, I., Nam, B., Lee, K. H., & Chung, H. C. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.017 · Cited by 140
Cullinan, S. A., Moertel, C. G., Wieand, H. S., O'Connell, M. J., Poon, M. A., Krook, J. E., Mailliard, J. A., & Tschetter, L. K. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.412 · Cited by 134
Lee, J.-L., Kang, Y.-K., Kang, H. J., Lee, K.-H., Zang, D. Y., Ryoo, B.-Y., Kim, J. G., Park, S. R., Kang, W. K., Shin, D. B., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604536 · Cited by 134
Lorenzen, S., Hentrich, M., Haberl, C., Heinemann, V., Schuster, T., Seroneit, T., Röthling, N., Peschel, C., & Lordick, F. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm269 · Cited by 132
Systematic Reviews of Evaluations of Prognostic Variables
Altman, D. G. (2001) · Wiley eBooks · doi:10.1002/9780470693926.ch13 · Cited by 126
Optimal chemotherapy for advanced gastric cancer: is there a global consensus?
Lordick, F., Lorenzen, S., Yamada, Y., & Ilson, D. H. (2013) · Gastric Cancer · doi:10.1007/s10120-013-0297-z · Cited by 118
Shirao, K., Boku, N., Yamada, Y., Yamaguchi, K., Doi, T., Goto, M., Nasu, J., Denda, T., Hamamoto, Y., Takashima, A., et al. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt114 · Cited by 117
on behalf of the Australasian Gastro-Intestinal Trials Group, Tebbutt, N. C., Cummins, M. M., Sourjina, T., Strickland, A. H., van Hazel, G., Ganju, V., Gibbs, D. D., Stockler, M. R., Gebski, V., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605522 · Cited by 113
Thuss-Patience, P. C., Kretzschmar, A., Repp, M., Kingreen, D., Hennesser, D., Micheel, S., Pink, D., Scholz, C. W., Dörken, B., & Reichardt, P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.163 · Cited by 113
Kono, K., Takahashi, A., Ichihara, F., Amemiya, H., Iizuka, H., Fujii, H., Sekikawa, T., & Matsumoto, Y. (2002) · PubMed · Cited by 112
Wang, J., Xu, R., Li, J., Bai, Y., Liu, T., Jiao, S., Dai, G., Xu, J., Liu, Y., Fan, N., et al. (2015) · Gastric Cancer · doi:10.1007/s10120-015-0457-4 · Cited by 108
Kang, Y., Satoh, T., Ryu, M., Chao, Y., Kato, K., Chung, H. C., Chen, J., Muro, K., Kang, W. K., Yoshikawa, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.2 · Cited by 107
Cocconi, G., Bella, M. A., Zironi, S., Algeri, R., Costanzo, F. D., Lisi, V. D., Luppi, G., Mazzocchi, B., Rodinò, C., & Soldani, M. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2687 · Cited by 105
Douglass, H. O., Lavin, P. T., Goudsmit, A., Klaassen, D. J., & Paul, A. R. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.12.1372 · Cited by 105
Moehler, M. H., Eimermacher, A., Siebler, J., Höhler, T., Wein, A., Menges, M., Flieger, D., Junginger, T., Geer, T., Gracien, E., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602649 · Cited by 97
Self-citationAjani, J. A., Lee, F.-C., Singh, D. A., Haller, D. G., Lenz, H., Benson, A. B., Yanagihara, R. H., Phan, A. T., Yao, J. C., & Strumberg, D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2994 · Cited by 91
Paolettí, X., Oba, K., Bang, Y., Bleiberg, H., Boku, N., Bouché, O., Catalano, P. J., Fuse, N., Michiels, S., Moehler, M. H., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt269 · Cited by 90
Self-citationCutsem, E. V., Kang, Y., Chung, H., Shen, L., Sawaki, A., Lordick, F., Hill, J., Lehle, M., Feyereislova, A., & Bang, Y. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.lba4509 · Cited by 90
The role of Helicobacter pylori infection in the web of gastric cancer causation
Peleteiro, B., Vecchia, C. L., & Lunet, N. (2011) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e32834a7f66 · Cited by 88
Tebbutt, N. C., Norman, A., Cunningham, D., Iveson, T. J., Seymour, M., Hickish, T., Harper, P., Maisey, N. R., Mochlinski, K., Prior, Y., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf273 · Cited by 86
Kang, Y., Shah, M. A., Ohtsu, A., Cutsem, E. V., Ajani, J. A., van der Horst, T., Harle-Yge, M.-L., Piao, Y., Althaus, B., & Thuss-Patience, P. C. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.5 · Cited by 83
Ajani, J. A., Buyse, M. E., Lichinitser, M., Горбунова, В. А., Bodoky, G., Douillard, J., Cascinu, S., Heinemann, V., Zaucha, R., Carrato, A., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.07.003 · Cited by 82
Sym, S. J., Hong, J., Park, J., Cho, E. K., Lee, J. H., Park, Y. H., Lee, W. K., Chung, M., Kim, H.-S., Park, S. H., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2027-3 · Cited by 80
Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer
Al‐Batran, S., & Ajani, J. A. (2010) · Cancer · doi:10.1002/cncr.25064 · Cited by 76
Syn, N. L. X., Yong, W. P., Goh, B. C., & Lee, S. C. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1196187 · Cited by 75
Self-citationLevi, J. A., Fox, R. M., Tattersall, M. H. N., Woods, R. L., Thomson, D. B., & Gill, G. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.9.1348 · Cited by 72
Nordin, K., Steel, J., Hoffman, K., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2046 · Cited by 71
One-year survey of carcinoma of the oesophagus and stomach in Wales
Pye, J. K., Crumplin, M. K. H., Charles, J., Kerwat, R., Foster, M. E., & Biffin, A. (2001) · British journal of surgery · doi:10.1046/j.1365-2168.2001.01655.x · Cited by 71
Samuels, B. L., Herndon, J. E., Harmon, D. C., Carey, R. W., Aisner, J., Corson, J. M., Suzuki, Y., Green, M. R., & Vogelzang, N. J. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980415)82:8<1460::aid-cncr5>3.0.co;2-d · Cited by 69
Lutz, M. P., Wilke, H., Wagener, D. J. T., Vanhoefer, U. J., Jeziorski, K., Hegewisch‐Becker, S., Balleisen, L., Joosens, E., Jansen, R. L., Debois, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.1666 · Cited by 69
Thirty years of medical research council randomized trials in solid tumours
Machin, D., Stenning, S. P., Parmar, M., Fayers, P. M., Girling, D. J., Stephens, R. J., Stewart, L. A., & Whaley, J. B. (1997) · Clinical Oncology · doi:10.1016/s0936-6555(05)80448-0 · Cited by 68
Chemotherapy for advanced gastric cancer
Wagner, D., Grothe, W. W., Behl, S., Kleber, G., Grothey, A. A., Haerting, J., & Fleig, W. E. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub2 · Cited by 68
Self-citationThuss-Patience, P. C., Kretzschmar, A., Deist, T., Hinke, A., Bichev, D., Lebedinzew, B., Schumacher, G., Gebauer, B., Maier, V., & Reichardt, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.4540 · Cited by 65
Cocconi, G., Carlini, P., Gamboni, A., Gasperoni, S., Rodinò, C., Zironi, S., Bisagni, G., Porrozzi, S., Cognetti, F., Costanzo, F. D., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg329 · Cited by 64
Molecular-targeted first-line therapy for advanced gastric cancer
Song, H., Zhu, J., & Lu, D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011461.pub2 · Cited by 62
Phase II trial of UFT in advanced colorectal and gastric cancer
Malik, S., Talbot, D. C., Clarke, P., et al. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.431 · Cited by 60
Docetaxel, Cisplatin, and Fluorouracil in Gastric Cancer: Does the Punishment Fit the Crime?
Ilson, D. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2210 · Cited by 58
Moehler, M. H., Kanzler, S., Geißler, M., Raedle, J., Ebert, M., Daum, S., Flieger, D., Seufferlein, T. T. W., Galle, P. R., & Hoehler, T. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp269 · Cited by 54
Self-citationYun, J., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., & Kang, W. K. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.015 · Cited by 50
Sadighi, S., Mohagheghi, M. A., Montazeri, A., & Sadighi, Z. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-274 · Cited by 47
Chen, X., Chen, X., Chen, Y., Liao, Y., Li, H., Wang, L., Yang, K., Li, K., Hu, J., Zhang, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060320 · Cited by 44
Lisi, V. D., Cocconi, G., Tonato, M., Costanzo, F. D., Leonardi, F., & Soldani, M. (1986) · PubMed · Cited by 43
Kurihara, M., Izumi, T., Yoshida, S., et al. (1991) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1991.tb01894.x · Cited by 42
Curran, D., Pozzo, C., Załuski, J., Dank, M., Barone, C., Valvere, V., Yalçın, Ş., Peschel, C., Wenczl, M., Göker, E., et al. (2009) · Quality of Life Research · doi:10.1007/s11136-009-9493-z · Cited by 40
Park, S. H., Nam, E., Park, J., Cho, E. K., Shin, D. B., Lee, J. H., Lee, W. K., Chung, M., & Lee, S. I. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm502 · Cited by 39
Botsen, D., Ordan, M., Barbe, C., Mazza, C., Perrier, M., Moreau, J., Brasseur, M., Renard, Y., Taillière, B., Slimano, F., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4860-1 · Cited by 37
Dixon, M. E. B., Mahar, A. L., Helyer, L. K., Vasilevska-Ristovska, J. Z., Law, C., & Coburn, N. G. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0442-3 · Cited by 36
Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer
Marcelo Garrido, S., Fonseca, P. J., Viéitez, J. M., Frunza, M., & Lacave, Á. J. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.915194 · Cited by 36
PSK may suppress CD57+ T cells to improve survival of advanced gastric cancer patients
Akagi, J., & Baba, H. (2010) · International Journal of Clinical Oncology · doi:10.1007/s10147-010-0033-1 · Cited by 33
Ochenduszko, S. L., Püsküllüoğlu, M., Konopka, K. W., Fijorek, K., Urbańczyk, K., Budzynski, A. Z., Matłok, M., Lazar, A., Sińczak-Kuta, A., Pędziwiatr, M., et al. (2015) · Medical Oncology · doi:10.1007/s12032-015-0687-7 · Cited by 32
Irinotecan in the treatment of gastric cancer
Bugat, R. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg727 · Cited by 29
Gastrointestinal Tumor Study Group (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.13.1011 · Cited by 28
Roth, A., Kolarić, K., Županc, D., Orešić, V., Roth, A., & Ebling, Z. (1999) · Tumori Journal · doi:10.1177/030089169908500404 · Cited by 27
Second-Line Treatment of Advanced Gastric Cancer with Oxaliplatin plus Raltitrexed
Schmid, K. E., Kornek, G. V., Schüll, B., Raderer, M., Lenauer, A., Depisch, D., Lang, F., & Scheithauer, W. (2003) · Oncology Research and Treatment · doi:10.1159/000071621 · Cited by 24
Ocvirk, J., Reberšek, M., Škof, E., Hlebanja, Z., & Boc, M. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31820dc0b0 · Cited by 24
Kim, T. W., Choi, S.-L., Ahn, J., Bang, H. S., Chang, H. M., Kang, Y. K., Lee, J. S., Kim, W. K., & Kim, S. H. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)81651-8 · Cited by 23
Kolarić, K., Potrebica, V., & Stanovnik, M. (2009) · Oncology · doi:10.1159/000226337 · Cited by 22
Mamede, M. H., Saga, T., Ishimori, T., Nakamoto, Y., Sato, N., Higashi, T., Mukai, T., Kobayashi, H., & Konishi, J. (2003) · Neoplasia · doi:10.1016/s1476-5586(03)80010-6 · Cited by 22
5-Fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma
Loehrer, P. J., Harry, D., & Chlebowski, R. T. (1994) · Investigational New Drugs · doi:10.1007/bf00873238 · Cited by 22
Genetic factors affecting drug disposition in Asian cancer patients
Syn, N. L. X., Yong, W. P., Lee, S. C., & Goh, B.-C. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1108964 · Cited by 21
Self-citationRidwelski, K., Fahlke, J., Kettner, E., Schmidt, C., Keilholz, U., Quietzsch, D., Aßmann, M., Stauch, M. B., Zierau, K., & Lippert, H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4512 · Cited by 20
Kim, Y. S., Sym, S. J., Park, S. H., Park, I., Hong, J., Ahn, H. K., Park, J., Cho, E. K., Lee, W. K., Chung, M., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2334-3 · Cited by 19
Cascinu, S., Galizia, G., Labianca, R., Ferraù, F., Pucci, F., Silva, R. R., Luppi, G., Beretta, G. D., Berardi, R., & Scartozzi, M. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1424-8 · Cited by 19
Roy, A. C., Cunningham, D., Hawkins, R. E., Sørbye, H., Adenis, A., Barcelo, J.-R., López-Vivanco, G., Adler, G., Canon, J.-L., Lofts, F. J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.286 · Cited by 19
Colucci, G., Giotta, F., Maiello, E., Cifarelli, R. A., Leo, S., Giuliani, F., Pezzella, G., Pedicini, A., & Valori, V. M. (1995) · American Journal of Clinical Oncology · doi:10.1097/00000421-199512000-00012 · Cited by 18
Bodoky, G., Scheulen, M. E., Rivera, F., Jassem, J., Carrato, A., Moiseyenko, V. M., Vynnychenko, I. O., Prausová, J., Laethem, J. V., Cascinu, S., et al. (2015) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-014-9680-1 · Cited by 17
Kang, Y., Lee, J., Min, Y., Lee, K., Zang, D. Y., Ryoo, B., Kim, J., Park, S. H., Kang, W., & Shin, D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4546 · Cited by 11
Taal, B. G., Huinink, W. W. T. B., Simonetti, G., Franklin, H., & McVie, J. G. (1990) · Cancer Investigation · doi:10.3109/07357909009012074 · Cited by 9
Kikuchi, K., Wakui, A., Shimizu, H., & Kunii, Y. (1990) · PubMed · Cited by 9
Yamamura, Y., Miyazaki, I., Ogawa, M., Yonemura, Y., TANEMURA, H., Kito, T., Hamajima, N., Saji, S., & Kosaka, T. (1998) · PubMed · Cited by 8
Morita, S., Baba, H., Tsuburaya, A., Takiuchi, H., Matsui, T., Maehara, Y., & Sakamoto, J. (2007) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hym046 · Cited by 7
[Randomized controlled trial of MMC + UFT and MMC + 5-FU therapy in advanced gastric cancer].
Sasagawa, T., Ho, N., Endo, T., et al. (1994) · PubMed · Cited by 4
562 High doses of epirubicin and 5-fluorouracil with or without cisplatin in advanced gastric cancer
Roth, A. D., Kolarić, K., & Županc, D. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)95816-o · Cited by 2
Cited by
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J. H., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055531 · Cited by 6,334
Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C., & Lordick, F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31288-5 · Cited by 4,803
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784
Metadata
- Authors
- Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-08-29
- Volume
- 2017
- Issue
- 8
- Pages
- CD004064-CD004064
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1875373156
- Cited by
- 1,299
- References
- 166
- FWCI
- 74.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.